CO5150190A1 - Nuevos analogos de prostaglandina f que ocurren naturalmente y metodos de utilizar tales nuevos analogos de prostaglandina f - Google Patents
Nuevos analogos de prostaglandina f que ocurren naturalmente y metodos de utilizar tales nuevos analogos de prostaglandina fInfo
- Publication number
- CO5150190A1 CO5150190A1 CO00016015A CO00016015A CO5150190A1 CO 5150190 A1 CO5150190 A1 CO 5150190A1 CO 00016015 A CO00016015 A CO 00016015A CO 00016015 A CO00016015 A CO 00016015A CO 5150190 A1 CO5150190 A1 CO 5150190A1
- Authority
- CO
- Colombia
- Prior art keywords
- prostaglandina
- compounds
- new analogs
- present
- methods
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000020084 Bone disease Diseases 0.000 abstract 2
- 150000001408 amides Chemical class 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/36—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/26—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being saturated and containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/02—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
- C07C251/04—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C251/06—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/51—Y being a hydrogen or a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C327/00—Thiocarboxylic acids
- C07C327/20—Esters of monothiocarboxylic acids
- C07C327/22—Esters of monothiocarboxylic acids having carbon atoms of esterified thiocarboxyl groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/185—Saturated compounds having only one carboxyl group and containing keto groups
- C07C59/215—Saturated compounds having only one carboxyl group and containing keto groups containing singly bound oxygen containing groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
- C07C59/56—Unsaturated compounds containing hydroxy or O-metal groups containing halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/40—Radicals substituted by oxygen atoms
- C07D307/46—Doubly bound oxygen atoms, or two oxygen atoms singly bound to the same carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/66—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/80—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/56—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Furan Compounds (AREA)
Abstract
La presente invención se refiere a nuevos análogos de PGF, en particular, la presente invención se refiere a compuestos que tienen una estructura según la siguiente formula:<EMI FILE="00016015_1" ID="1" IMF=JPEG >En donde R1, X, y Z son como se definen más adelante.Esta invención también incluye isómeros ópticos, diastereómeros y enantiómeros de la fórmula antes mencionada, y sales farmacéuticamente aceptables, amidas biohidrolizables, ésteres y amidas de estos.Los compuestos de la presente invención son útiles para el tratamiento de una variedad de enfermedades y condiciones, tales como trastornos óseos. Por consiguiente, la invención provee adicionalmente composiciones farmacéuticas que comprenden estos compuestos. La invención provee adicionalmente métodos para el tratamiento de trastornos óseos utilizando estos compuestos o las composiciones que las contienen.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12292999P | 1999-03-05 | 1999-03-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5150190A1 true CO5150190A1 (es) | 2002-04-29 |
Family
ID=22405703
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO00016015A CO5150190A1 (es) | 1999-03-05 | 2000-03-06 | Nuevos analogos de prostaglandina f que ocurren naturalmente y metodos de utilizar tales nuevos analogos de prostaglandina f |
Country Status (20)
Country | Link |
---|---|
US (1) | US6451859B1 (es) |
EP (1) | EP1159265B1 (es) |
JP (1) | JP2002538138A (es) |
KR (1) | KR20010102509A (es) |
CN (1) | CN1382121A (es) |
AT (1) | ATE283256T1 (es) |
AU (1) | AU763715B2 (es) |
BR (1) | BR0008778A (es) |
CA (1) | CA2364944C (es) |
CO (1) | CO5150190A1 (es) |
CZ (1) | CZ20013175A3 (es) |
DE (1) | DE60016181T2 (es) |
ES (1) | ES2233351T3 (es) |
HU (1) | HUP0200365A2 (es) |
IL (1) | IL145123A0 (es) |
MX (1) | MXPA01008956A (es) |
NO (1) | NO20014240L (es) |
NZ (1) | NZ513826A (es) |
PL (1) | PL352551A1 (es) |
WO (1) | WO2000051979A1 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2232434T3 (es) | 1999-03-05 | 2005-06-01 | Duke University | Analogos de prostaglandinas c-16 fp selectivas insaturadas. |
CA2364944C (en) * | 1999-03-05 | 2009-01-20 | The Procter & Gamble Company | C16 unsaturated fp-selective prostaglandins analogs |
US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
US20020037914A1 (en) | 2000-03-31 | 2002-03-28 | Delong Mitchell Anthony | Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins |
US20020172693A1 (en) | 2000-03-31 | 2002-11-21 | Delong Michell Anthony | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
US6586462B2 (en) * | 2000-10-20 | 2003-07-01 | Allergan, Inc. | ω-Cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists |
KR100437873B1 (ko) * | 2001-05-08 | 2004-06-26 | 연성정밀화학(주) | 프로스타글란딘 유도체의 제조방법 및 그의 입체특이적출발물질 |
US20060135609A1 (en) * | 2004-10-21 | 2006-06-22 | Duke University | Ophthamological drugs |
US20070254920A1 (en) * | 2006-04-26 | 2007-11-01 | Aerie Pharmaceuticals, Inc. | Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use |
US8722739B2 (en) | 2008-10-29 | 2014-05-13 | Novaer Holdings, Inc. | Amino acid salts of prostaglandins |
US8623918B2 (en) | 2008-10-29 | 2014-01-07 | Novaer Holdings, Inc. | Amino acid salts of prostaglandins |
US20110293549A1 (en) | 2009-02-03 | 2011-12-01 | Athena Cosmetics, Inc. | Composition, method and kit for enhancing hair |
WO2010108012A1 (en) * | 2009-03-18 | 2010-09-23 | Duke University | Compositions and methods for promoting nasal patency and treating neurogenic bladder using prostaglandins |
CN102040618B (zh) * | 2009-04-30 | 2013-09-04 | 上海天伟生物制药有限公司 | 一种PGF2a类似物的制备方法及其相关中间体 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1520522A (en) * | 1975-06-16 | 1978-08-09 | Ono Pharmaceutical Co | 16-methyleneprostaglandins |
WO1994008585A1 (en) * | 1992-10-13 | 1994-04-28 | Alcon Laboratories, Inc. | Combinations of prostaglandins and clonidine derivatives for the treatment of glaucoma |
ID24827A (id) * | 1997-09-09 | 2000-08-24 | Procter & Gamble | Metoda peningkatan volume tulang dengan menggunakan agonis fp selektif yang terjadi secara non-alami |
CA2364944C (en) * | 1999-03-05 | 2009-01-20 | The Procter & Gamble Company | C16 unsaturated fp-selective prostaglandins analogs |
-
2000
- 2000-02-29 CA CA002364944A patent/CA2364944C/en not_active Expired - Lifetime
- 2000-02-29 WO PCT/US2000/005299 patent/WO2000051979A1/en not_active Application Discontinuation
- 2000-02-29 CZ CZ20013175A patent/CZ20013175A3/cs unknown
- 2000-02-29 AT AT00914785T patent/ATE283256T1/de not_active IP Right Cessation
- 2000-02-29 CN CN00807178A patent/CN1382121A/zh active Pending
- 2000-02-29 ES ES00914785T patent/ES2233351T3/es not_active Expired - Lifetime
- 2000-02-29 JP JP2000602207A patent/JP2002538138A/ja not_active Withdrawn
- 2000-02-29 AU AU36130/00A patent/AU763715B2/en not_active Expired
- 2000-02-29 EP EP00914785A patent/EP1159265B1/en not_active Expired - Lifetime
- 2000-02-29 BR BR0008778-5A patent/BR0008778A/pt not_active IP Right Cessation
- 2000-02-29 DE DE60016181T patent/DE60016181T2/de not_active Expired - Lifetime
- 2000-02-29 HU HU0200365A patent/HUP0200365A2/hu unknown
- 2000-02-29 PL PL00352551A patent/PL352551A1/xx not_active Application Discontinuation
- 2000-02-29 KR KR1020017011305A patent/KR20010102509A/ko not_active Application Discontinuation
- 2000-02-29 US US09/914,531 patent/US6451859B1/en not_active Expired - Lifetime
- 2000-02-29 NZ NZ513826A patent/NZ513826A/en unknown
- 2000-02-29 IL IL14512300A patent/IL145123A0/xx unknown
- 2000-02-29 MX MXPA01008956A patent/MXPA01008956A/es not_active Application Discontinuation
- 2000-03-06 CO CO00016015A patent/CO5150190A1/es unknown
-
2001
- 2001-08-31 NO NO20014240A patent/NO20014240L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CZ20013175A3 (cs) | 2002-02-13 |
IL145123A0 (en) | 2002-06-30 |
CN1382121A (zh) | 2002-11-27 |
JP2002538138A (ja) | 2002-11-12 |
ES2233351T3 (es) | 2005-06-16 |
ATE283256T1 (de) | 2004-12-15 |
DE60016181T2 (de) | 2005-04-14 |
AU763715B2 (en) | 2003-07-31 |
AU3613000A (en) | 2000-09-21 |
NO20014240D0 (no) | 2001-08-31 |
CA2364944A1 (en) | 2000-09-08 |
US6451859B1 (en) | 2002-09-17 |
MXPA01008956A (es) | 2002-04-24 |
BR0008778A (pt) | 2001-12-18 |
DE60016181D1 (de) | 2004-12-30 |
CA2364944C (en) | 2009-01-20 |
EP1159265A1 (en) | 2001-12-05 |
HUP0200365A2 (hu) | 2002-07-29 |
KR20010102509A (ko) | 2001-11-15 |
NO20014240L (no) | 2001-11-02 |
WO2000051979A1 (en) | 2000-09-08 |
NZ513826A (en) | 2001-09-28 |
PL352551A1 (en) | 2003-08-25 |
EP1159265B1 (en) | 2004-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5150190A1 (es) | Nuevos analogos de prostaglandina f que ocurren naturalmente y metodos de utilizar tales nuevos analogos de prostaglandina f | |
CO5160251A1 (es) | Analogos de prostaglandinas selectivos del receptor fp c16 insaturados | |
AR013477A1 (es) | Prostaglandinas de tetrahidro sustituido c16-20 aromatico utiles como agonistas de fp. | |
AR012264A1 (es) | Compuesto, composicion farmaceutica y metodo para obtener la composicion para prevenir o evitar una enfermedad asociada a actividad metaloproteasicaindeseada | |
UY29412A1 (es) | Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos. | |
UY24409A1 (es) | Inhibidores de la matriz metaloproteasa | |
AR050261A2 (es) | Aminoacidos con afinidad por la proteina alfa-2-delta y composiciones farmaceuticas que los contienen y su uso para preparar un medicamento | |
AR021844A1 (es) | Derivados de propanolamina aril-sustituidos, procedimientos para su preparacion, medicamentos que contienen estos compuestos y su utilizacion | |
BR9811779A (pt) | Tetrahidro prostaglandina s substituìdas por c16-c20 aromáticos úteis como agonistas fp | |
BR9713462A (pt) | Métodos para produção de compostos carotenóides e óleos especiais em sementes de plantas. | |
CO5180578A1 (es) | Inhibidores de metaloproteasas dihetero substituida que son efectivos en el tratamiento de condiciones caracterizadas por la actividad excesiva de estas enzimas | |
ES2179353T3 (es) | Antagonistas muscarinicos. | |
AR024060A1 (es) | Nuevos compuestos farmaceuticamente activos | |
ECSP056192A (es) | 3-fluoro-piperidinas como antagonistas de nmda/nr2b | |
BR9812631A (pt) | Tetraidro prostaglandinas substituìdas por c16-c20 aromáticos úteis como agonistas de fp | |
UY28279A1 (es) | Fenacilo 2 -hidroxi - 3 - diaminoalcanos | |
AR009358A1 (es) | Compuesto espirociclico inhibidor de la metaloproteasa | |
AR015448A1 (es) | COMBINACIoN DE UN INHIBIDOR DE REABSORCIoN DE 5-HT CON UN ANTAGONISTA O AGONISTA PARCIAL DE H5-HT1B, PROCESO PARA SU PREPARACIoN, FORMULACIoN FARMACÉUTICA QUE LA CONTIENE, SU USO PARA PREPARAR MEDICAMENTOS PARA TRATAR TRASTORNOS AFECTIVOS Y KIT QUE CONTIENE DICHA COMBINACIoN | |
UY25519A1 (es) | Procedimiento para preparar antagonista del receptor de vitronectina | |
ES2202156T3 (es) | Nuevos analogos de 2-descarboxi-2-fosfinico prostaglandina f. | |
ES2167021T3 (es) | Derivados de acido 4-bifenil-4-hidroxibutirico sustituidos como inhibidores de metaloproteasa de matriz. | |
CO5271694A1 (es) | Inhibidores beta di-sustituidos de las metaloproteasas, composiciones farmaceuticas que los contienen y procedimientos para su aplicacion | |
UY27034A1 (es) | Derivados de pirimidina | |
AR032622A1 (es) | Compuestos de 4-amino-azepan-3-ona, composiciones farmaceuticas que los comprenden, intermediarios utiles en la sintesis de tales compuestos, procedimiento para la sintesis de dichos compuestos, y uso de tales compuestos en la fabricacion de medicamentos | |
BR9909267A (pt) | C11 oximila e prostaglandinas hidroxilamino úteis como medicamentos |